The biology of mammary transgenes: Five rules
暂无分享,去创建一个
[1] R. Cardiff,et al. Comparative pathology of mammary tumorigenesis in transgenic mice. , 1995, Cancer letters.
[2] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[3] W. Muller,et al. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.
[4] M. Barinaga. Knockout mice: round two. , 1994, Science.
[5] Emma Lees,et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.
[6] L. Hennighausen,et al. Whey acidic protein extrinsically expressed from the mouse mammary tumor virus long terminal repeat results in hyperplasia of the coagulation gland epithelium and impaired mammary development. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[7] Z. Werb,et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression [published erratum appears in J Cell Biol 1996 Feb;132(4):following 752] , 1994, The Journal of cell biology.
[8] B. Hogan,et al. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. , 1994, Cancer research.
[9] R. Coffey,et al. Cause of Failure of Lactation in Mouse Mammary Tumor Virus/Human Transforming Growth Factor α Transgenic Mice , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[10] W. Muller,et al. Mammary tumorigenesis and metastasis in transgenic mice. , 1994, Seminars in cancer biology.
[11] W. Muller,et al. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.
[12] R. Weinberg,et al. Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.
[13] H. Westphal,et al. Timing of SV40 oncogene activation by site-specific recombination determines subsequent tumor progression during murine lens development. , 1993, Oncogene.
[14] B. Hogan,et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. , 1993, Genes & development.
[15] W. Muller,et al. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. , 1993, Oncogene.
[16] R. Cardiff,et al. Multiple tumor types appear in a transgenic mouse with the ras oncogene. , 1993, The American journal of pathology.
[17] H. Varmus,et al. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] R. Mangues,et al. Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. , 1992, Oncogene.
[20] B. Carlsson,et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[21] R. Guzman,et al. Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice. , 1992, Cancer research.
[22] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Cardiff,et al. Int-2, an autocrine and/or ultra-short-range effector in transgenic mammary tissue transplants. , 1992, Journal of the National Cancer Institute.
[24] B. Hogan,et al. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. , 1992, The American journal of pathology.
[25] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[26] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[27] D. Gallahan,et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. , 1992, Genes & development.
[28] H. Varmus,et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.
[29] S. Cory,et al. Transgenic models of tumor development. , 1991, Science.
[30] G. Merlino,et al. Molecular insights into breast cancer from transgenic mouse models , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.
[31] W. Muller. Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer , 1991, Cancer and Metastasis Reviews.
[32] R. Cardiff,et al. Transgenic oncogene mice. Tumor phenotype predicts genotype. , 1991, The American journal of pathology.
[33] L. Nielsen,et al. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. , 1991, Cancer research.
[34] A. Harris,et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.
[35] P. Leder,et al. Binary system for regulating transgene expression in mice: targeting int-2 gene expression with yeast GAL4/UAS control elements. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Fourney,et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.
[37] L. Orci,et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.
[38] B. Hogan,et al. Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.
[39] D. Roop,et al. Differential keratin gene expression in developing, differentiating, preneoplastic, and neoplastic mouse mammary epithelium. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[40] R. Callahan,et al. Mutations in human breast cancer: an overview. , 1989, Journal of the National Cancer Institute.
[41] P. Leder,et al. Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. , 1989, The American journal of pathology.
[42] P. Jolicoeur,et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.
[43] T. Hoang,et al. Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues , 1989, Molecular and cellular biology.
[44] B. Groner,et al. Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. , 1988, Genes & development.
[45] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[46] B. Groner,et al. Targeted c‐myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. , 1988, The EMBO journal.
[47] P. Leder,et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.
[48] B. Groner,et al. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[49] N. Glaichenhaus. [Cooperation between oncogenes: the function of immortalizing oncogenes]. , 1986, Pathologie-biologie.
[50] Alan E. Smith,et al. Polyoma virus transforming protein associates with the product of the c-src cellular gene , 1983, Nature.
[51] R. Cardiff,et al. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.
[52] R. Cardiff,et al. Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.
[53] R. Cardiff,et al. Mammary Morphogenesis and Oncogenes , 1992 .
[54] B. Hogan,et al. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.
[55] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[56] R. Cardiff. Protoneoplasia: the molecular biology of murine mammary hyperplasia. , 1984, Advances in cancer research.
[57] F. X. Demers,et al. [Mammary tumors]. , 1957, Laval medical.